Get started
PALATIN TECHNOLOGIES INC COM USD0.01 (POST REV SPLIT)PALATIN TECHNOLOGIES INC COM USD0.01 (POST REV SPLIT)PALATIN TECHNOLOGIES INC COM USD0.01 (POST REV SPLIT)

PALATIN TECHNOLOGIES INC COM USD0.01 (POST REV SPLIT)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0KF3 trade ideas

PTN - Promising News and upcoming CatalystsPalatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Disclaimer: This content is for informational purposes only and should not be construed as financial advice. Investment Overview (Dated 02/05/2024): Shares in Float: 15.44 million shares Short Float: 9.01% Upcoming Catalysts: Four major catalysts anticipated in 2024 Recent Developments: Positive news impacting the stock Critical Resistance Levels: Resistance is observed at $2.40, $2.80, $3.00, and $3.60. Surpassing these levels may suggest a continuation of the upward trend. Trading Strategy: Take Profit (TP): Target a take-profit point at approximately $3.90 to maximize returns. Stop Loss (SL): Implement a stop loss strategy at slightly below $1.85 to mitigate risk. Chart Analysis: Details: For detailed analysis of price movements and trend lines, please see the accompanying chart. Trading Caution: Risk Management: Trading requires careful consideration of market conditions and personal risk tolerance. It is advisable to perform thorough research or consult a financial advisor before making any investment decisions.
AMEX:PTNLong
by meitshels_smell_trades
Bullish Cypher Pattern on PTN ChartThis pattern gives a first target to return to level A at about 8.10-8.20 and a second target to return to level C at around 8.50. Anticipated Catalysts for remaining 2022: NA/US Licensing Vyleesi ROW Licensing Vyleesi PL3994 PH2 Heart Failure Data Diabetic Nephropathy PH 2 Initiate Study Something should also happen with the preferred shares at the end of September. (Convertible at $11.25 to common shares, Redeemed for debt, or basically cancelled)
AMEX:PTNLong
by muhley
$PTN entry PT .70-.75 Target PT 1.59 Long term PT 5 and higher$PTN H.C. Wainwright analyst Joseph Pantginis is behind today’s news as he reiterated the firm’s buy rating for PTN stock. To go along with that, Pantginis also increased the price target for PTN stock from $2 per share to $5 per share, 1,371% upside Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
AMEX:PTNLong
by BADQOMOCAWGOWLD
Palatin Technologies 500%+ Expected ReturnCompany Profile Sector: Health Care Industry: Biotechnology Company Location: Cranbury, NJ Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor 12 Month Price Targets: High: $5.00 Mean: $3.00 Low: $2.00 News: --HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating MT NEWSWIRES 7:18 AM ET 11/24/2021 07:18 AM EST, 11/24/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: www.mtnewswires.com) Price: 0.3800, Change: +0.04, Percent Change: +10.34 MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
AMEX:PTNLong
by thedailyinvestor
PTN - Movement on News, Article and YouTube VideosI just created this chart to better understand how PTN moved on the big spike recently. Seems like it didn't take much, just a Yahoo article after the positive dry eye news and then a few YouTube videos. Here are the links to the article and videos: 12/22/2020 Michael Marcus - TipRanks tipranks.com/news/article/these-2-penny-stocks-are-poised-for-a-massive-rally-say-analysts 12/22/2020 JT Wealth - YouTube youtube.com/watch?v=H1mP74IQGng&t=20s 12/25/2020 Kenan Grace - YouTube youtube.com/watch?v=wlt93RTyN4M 12/27/2020 Kenan Grace - YouTube youtube.com/watch?v=5zpn10RupY8&t=13s 1/18/2021 Market Gains - Youtube youtube.com/watch?v=ufy7AaQF0Ak&t=51s 1/22/2021 Kenan Grace - YouTube youtube.com/watch?v=LNEAXrMQTyI&t=185s 3/25/2021 Kenan Grace - YouTube youtube.com/watch?v=B7YZDIALwF8&t=153s Potential Upcoming Catalysts Eye Preclinical - Next Anterior Indication Vyleesi - Korea PK Vyleesi - China PK PL9643 - PH2/3 Initiate Diabetic Retinopathy - File IND PL8177 IBD - PH2 Initiate Vyleesi - Multiple ROW deals Vyleesi - NA deal I would watch for the recent dry eye news or one of the above catalysts to result in another spike after new articles and videos are published.
AMEX:PTNLong
by muhley
Palatin Technologies - Bullish OutlookPalatin Technologies is a little known pharmaceutical company that specializes in the development of peptide drugs. Palatin Technologies (PTN) is severely undervalued with a Market Cap of about $180 Million as of 3/17/21. Palatin has $72.2 Million in cash on hand as of 12/31/2020, and no debt.* Palatin owns and recently began marketing FDA Approved Vyleesi, a drug to treat Hypoactive Sexual Desire Disorder in women. The drug also has potential to be studied for additional indications such as Erectile Disfunction in men. In December 2020, Palatin informed investors that they received positive results for the their PH2 dry eye drug study PL9643. According to the company, “PL9643 is a efficacious as Restasis® and several orders of magnitude more potent”.* *Source: palatin.com//assets/Palatin_Corp_Prest_March-2021-Final.pdf Like many other biotech companies, Palatin has relied on dilutive financing options to fund operations and pipeline development. During the period from June 30, 2016 until about June 30,2018 the outstanding share amount nearly tripled from 68,568,055 shares to a whopping 200,554,205 shares.* This was due primarily to the exercise of a substantial amount of warrants with a $.01 exercise price (penny warrants). These warrants resulted in heavy downward pressure on the stock price. *Sources sec.gov/Archives/edgar/data/0000911216/000165495416002272/ptn_10k.htm sec.gov/Archives/edgar/data/0000911216/000165495418010150/ptn_10k.htm Despite the heavy downward pressure from the penny warrants, the stock price of PTN was able to climb from below $.30 in April 2017 to reach a high above $1.50 in April of 2018. This was due to a string of good news* including the following: Positive phase 3 data for Vyleesi (bremelanotide). Signing of a licensing agreement for Vyleesi with AMAG Pharmaceuticals for the North America Territory. Signing of a licensing agreement for Vyleesi with Fosun for the China Territory. Signing of a licensing agreement for Vyleesi with Kwangdong for the Korea Territory. *Source: palatin.com/investors/press-releases In the Palatin’s FORM 10-K For the fiscal year ended June 30, 2018 it was disclosed that there were no more penny warrants outstanding.* As a result, the huge downward pressure of the penny warrants on the stock price was eliminated. *Source: sec.gov/Archives/edgar/data/0000911216/000165495418010150/ptn_10k.htm Palatin is sitting pretty today… Vyleesi remains a valuable asset that can be relicensed to a new partner for North American rights and ROW rights as well. Their dry eye drug is looking promising as well and they recently applied for an international patent for the drug. They also have a few other drug programs in the pipeline including other ocular indications, cardiovascular indications and inflammatory bowel disease. The company has a healthy balance sheet with no debt and cash on hand of $72.2 Million as of December 31, 2020. The closing price of the stock was $.7683 on 3/17/21. Where Palatin Technologies could go moving forward: Although they are having ongoing discussions, Palatin management has stated that they believe partnership talks for North American rights will ramp up later in the year for Vyleesi as well as for the rest of the world territories. Palatin is continuing to move forward with its PL9643 dry eye drug. The CEO of Palatin indicated in the Q1 2021 conference call that they “have had preliminary discussions with potentially larger companies that would be interested in a dry eye product.”* I believe if development of PL9643 continues to move forward it will catch the eyes of larger players in the industry and a partnership, asset purchase, or buyout of the company will occur. Novartis purchased Xiidra for $3.4 Billion upfront and up to $1.9 Billion in milestone payments.** The company is in a similar spot to where they were at before licensing Vyleesi to AMAG, but now they have the PL9643 dry eye drug with promising potential, as well as a few other drugs in the pipeline. *Source: seekingalpha.com/article/4389783-palatin-technologies-inc-ptn-ceo-carl-spana-on-q1-2021-results-earnings-call-transcript **Source: eyewire.news/articles/novartis-to-acquire-dry-eye-drug-xiidra-in-deal-worth-up-to-5-3-billion/ Potential upcoming catalysts: North America relicensing of Vyleesi. ROW licensing of Vyleesi. Developments of Vyleesi in existing licensed territories or China and Korea. Announcement on next eye indications (Anterior and Retinal Indications). Funding for a potential drug that treats effects in the lungs of COVID-19. Phase 2 clinical trials for the dry eye drug and an IBD (ulcerative colitis) drug. With cash in the bank, and with Vyleesi and PL9643 moving forward, PTN is severely undervalued. Palatin produced a string of good news in a period of heavy downward pressure on the stock price from penny warrants. Despite the downward pressure the stock still managed to move from about $.30 to over $1.50. If Palatin can produce a string of good news again we should see a much more significant move upward, now that downward penny warrant pressure is off. My One-Year price target is $5.00 ($1.37 Billion Market Cap). Disclaimer: Author is not a licensed financial advisor. This presentation is for educational purposes only. Do your own research. Author holds a long position in stock.
AMEX:PTNLong
by muhley
Solid CUP and HANDLE Canaccord Genuity analyst John Newman maintained a Buy rating on Palatin Technologies yesterday and set a price target of $3.00. According to TipRanks.com, Newman is a 5-star analyst with an average return of 24.5% and a 44.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Allogene Therapeutics. Currently, the analyst consensus on Palatin Technologies is a Strong Buy with an average price target of $2.17, a 442.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $2.00 price target.
AMEX:PTNLong
by gregchipps
1
Perfect CUP and HANDLE structure, massive potential upside!!Analysts have a price target between $2 and $3. Earnings report on 17 Feb 2021. They launch their first FDA-approved product Vyleesi to market in Q3 of 2020 which could potentially help 6 million women suffering from HSDD in the USA alone. This product generated $800 million in sales in Q3 and will grow over time as Palatin is currently the only company offering medicine for HSDD on the market. Also, they have a second potential billion-dollar product in the pipeline that could hit the market in 2021 which treats DED and has 16 million cases in the USA. As of June 30, 2020, the Company had $82.9 million in cash and cash equivalents, compared to $43.5 million as of June 30, 2019, and no debt. Their short-term liabilities are on average around €5 million. Besides this, the chart looks very bullish as it shows an almost perfect CUP and HANDLE structure. Giving the current mania in the market I wouldn't be surprised if this blows up after some positive news from their earnings report on 17 Feb. I am not a financial advisor, always do your own due diligence before buying any stock. This stock could potentially drop -50%, always add a stop-loss in penny stocks like this.
AMEX:PTNLong
by themstmoneymachine
1